In response to the significant need to intensify efforts at early diagnosis, this trial proposes further building on knowledge of the genetic basis of AL in clonal plasma cells. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease.
Screening for AL Amyloidosis in SMM
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma
All genders
40+
Recruiting now
Overview
Principal Investigator: Raymond Comenzo
Contact Us
Denis Toskic
Study details
Inclusion Criteria
- Patients 40 years of age and older diagnosed with either SMM or a monoclonal gammopathy
- dFLC greater than 23 mg/L and abnormal κ::λ FLC ratio
- If the patient has an eGFR less than 50 mL/min/1.73m2, the κ::λ FLC ratio is inconsequential. The patient only needs to meet the age and dFLC criteria in this case.
Exclusion Criteria
- Patients with a previous finding of amyloid in other biopsies will not be included
- Patients younger than 40 years of age are not eligible
- Adults unable to consent are not eligible, including the cognitively impaired. Pregnant women, pregnant minors, minors (i.e., individuals who are not yet adults), wards of the state, non-viable neonates, neonates of uncertain viability, and prisoners are not eligible
Study Requirements
One-time donation of bone marrow and peripheral blood samples.